Pharmacological strategies for reduction of lipid availability.
Foley
J E
JE
Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceutical Corporation, East Hanover, New Jersey 07936, USA.
Anderson
R C
RC
Bell
P A
PA
Burkey
B F
BF
Deems
R O
RO
de Souza
C
C
Dunning
B E
BE
D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000273:Adipose Tissue / Q000378:metabolism*; D000818:Animals; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D007333:Insulin Resistance; D008066:Lipolysis / Q000187:drug effects; D008297:Male; D051381:Rats
D005227:Fatty Acids; D007328:Insulin; C090949:N(6)-cyclohexyl-2-O-methyladenosine; D000241:Adenosine